Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors | Patent Number 11879013

US 11879013 B2
Application Number15931726
Publication NumberUS 20210017285 A1
Pendency3 years, 8 months, 14 days
Filled DateMay 14, 2020
Priority DateMay 14, 2019
Publication DateJan 21, 2021
Expiration DateMay 13, 2039
Inventor/ApplicantsSylvie Laquerre
Matthew Lorenzi
Sheri Moores
ExaminesALSOMAIRY, SARAH ABDOALATIF
Art Unit1642
Technology Center1600
Assignments
Janssen Biotech Inc.
Current
Janssen Biotech Inc.Johnson & Johnson
Original
Law Firm
You must be logged in to view
Login
Attorneys
Subscription-Only
View Concierge Program
Patent Prosecution report image

Empower your practice with Patexia Publication Prosecution IP Module.

Get access to our exclusive rankings and unlock powerful data.
Check our Latest ReportPurchase IP Module

Looking for a Publication Attorney?

Get in touch with our team or create your account to start exploring a network of over 120K attorneys.